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Abstract   31 
Candida auris has emerged as a multi-drug resistant nosocomial pathogen over the last 32 
decade. Outbreaks of the organism in healthcare facilities has resulted in life-threatening 33 
invasive candidiasis in over 40 countries worldwide. Resistance by C. auris to conventional 34 
antifungal drugs such as fluconazole and amphotericin B means that alternative 35 
therapeutics must be explored. As such, this study served to investigate the efficacy of a 36 
naturally derived polysaccharide called chitosan against aggregative (Agg) and non-37 
aggregative (non-Agg) isolates of C. auris in vitro and in vivo. In vitro results indicated that 38 
chitosan was effective against planktonic and sessile forms of Agg and non-Agg C. auris. In a 39 
Galleria mellonella model to assess C. auris virulence, chitosan treatment was shown to 40 
ameliorate killing effects of both C. auris phenotypes (NCPF 8973 and NCPF 8978, 41 
respectively) in vivo. Specifically, chitosan reduced the fungal load and increased survival 42 
rates of infected Galleria, whilst treatment alone was non-toxic to the larvae. Finally, 43 
chitosan treatment appeared to induce a stress-like gene expression response in NCPF 8973 44 
in the larvae likely arising from a protective response by the organism to resist antifungal 45 
activity of the compound. Taken together, results from this study demonstrate that 46 
naturally derived compounds such as chitosan may be useful alternatives to conventional 47 
antifungals against C. auris.   48 
Introduction 49 
Fungal diseases are highly prevalent; nearly a billion people worldwide are estimated to 50 
have skin, nail and hair fungal infections (1). Of these diseases, healthcare-associated fungal 51 
infections are commonplace. Recently, Candida auris has gained unprecedented attention 52 
due to its emergence as a prolific nosocomial pathogen. Since its first discovery in 2009 (2), 53 
the organism has reportedly been identified in over 40 countries on 6 different continents, 54 
with a crude mortality rate of 66% associated with C. auris candidemia (3). Coupled with the 55 
alarmingly high multi-drug resistance profile in C. auris, this organism provides a substantial 56 
global risk in healthcare facilities and intensive care units (4-6). In addition, the organism has 57 
the ability to persist environmentally, with suggestions that its emergence has coincided 58 
with climate change based on its particular attributes (7). In vitro studies have shown that 59 
standard and high-level strategies of disinfection are incapable of completely eradicating C. 60 
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auris off non-porous surfaces (8, 9), whilst cellular aggregates of C. auris can survive for as 61 
long as 14 days even following treatment with clinically relevant concentrations of sodium 62 
hypochlorite (10). As such, identification of new antifungal therapies is of utmost 63 
importance.   64 
Whole-genome sequencing of C. auris originally led to the identification of four 65 
geographically and phylogenetically distinct clades of the organism, each containing 66 
genetically identical strains with vast (>100,000) single nucleotide polymorphism (SNP) 67 
differences between clades (4). Recently, a fifth clade has been proposed, separated from 68 
other clades by >200,000 SNPs (11). Within these clades exist C. auris isolates that have two 69 
distinguishable phenotypes; aggregative (Agg) and non-aggregative (non-Agg) isolates (12). 70 
In the former, a characteristic accumulation of aggregates containing yeast cells attached to 71 
daughter cells after budding are visible in vitro, which cannot be physically disrupted. 72 
Furthermore, such aggregates have recently been isolated from harvested tissues of murine 73 
models infected with C. auris suggestive that such a phenotype can be observed in vivo (13). 74 
In vitro, the non-Agg phenotype, which are characterised by sparse, individual cellular 75 
entities, form biofilms with greater biomass than Agg counterparts (14). In a Galleria 76 
mellonella killing assay, non-Agg C. auris were significantly more virulent than the 77 
aggregate-forming isolates, resulting in increased larvae death (12, 14). The identification of 78 
these unique C. auris isolates from various clades further complicates antifungal 79 
susceptibility testing, particularly given the differences in virulence traits between the two 80 
phenotypes.     81 
Chitosan (poly-(β-1→4)-2-amino-2-deoxy-d-glucopyranose) is a naturally occurring, 82 
biodegradable, and non-toxic polysaccharide derived from deacetylated chitin (a constituent 83 
of fungal cell walls and crustacean exoskeletons), with wide spectrum antimicrobial activity 84 
against different microorganisms (15). As such, the antimicrobial polymer compound 85 
provides an exciting alternative to conventional antibacterial and/or antifungal therapeutics. 86 
Indeed, several studies have investigated the antifungal efficacy of chitosan or derivatives 87 
against a range of Candida species including C. albicans and other clinically relevant fungal 88 
species (16-20). At this juncture, the aim of this study was to test the ability of chitosan 89 
against non-Agg and Agg isolates of C. auris in vitro. Furthermore, chitosan efficacy was then 90 
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tested against two candidate C. auris isolates in vivo (one non-Agg isolate, NCPF 8973, and 91 
one Agg isolate, NCPF 8978) in a Galleria infection model.   92 
 93 
Methods  94 
Microbial growth  95 
Four Agg and four non-Agg isolates of C. auris were used in this study were kindly gifted by 96 
Dr Andy Borman (Public Health England). The eight isolates and their clades are shown in 97 
Table 1. These isolates were taken from various clinical sites (Public Health England National 98 
Collection of Pathogenic Fungi [NCPF]) as previously described (12, 21). The isolates were 99 
deemed aggregative if they could not be physically disrupted by vigorous vortex mixing or 100 
by detergent treatments as previously described (12).  101 
All isolates were stored in MicrobankTM beads (Pro-lab Diagnostics, UK) then grown at 30˚C 102 
for 24-48 h. All isolates were maintained on Sabouraud dextrose (SAB) agar (Oxoid, 103 
Hampshire, UK) at 4˚C prior to propagation in yeast peptone dextrose (YPD; Sigma-Aldrich, 104 
Dorset, UK) medium overnight (16 h) at 30˚C, gently shaking at 200 rpm. Cells were pelleted 105 
by centrifugation (3,000 x g) then washed two times in PBS. Fungal cells were then 106 
standardized to desired concentration after counting using a haemocytometer in 107 
appropriate media as described below.  108 
Planktonic and sessile susceptibility testing with chitosan 109 
Chitosan used throughout this study was purchased from Sigma-Aldrich (medium molecular 110 
weight, 75-85% deacetylated, cat. no. 448877). Chitosan stocks of 1.4 g/l were freshly 111 
prepared in 2% acetic acid, constantly stirring (200 rpm) for 24 h at room temperature until 112 
complete solubilisation as previously described (22, 23). All subsequent studies were then 113 
completed in accordance with the minimum information guidelines specified for planktonic 114 
and/or biofilm testing in microplates (24). Where appropriate, Clinical and Laboratory 115 
Standards Institute (CLSI) guidelines were followed for all planktonic susceptibility tests (25).  116 
Firstly, the broth microdilution method (25) was used to determine the minimum inhibitory 117 
concentration (MIC) of chitosan on planktonic C. auris cells (pMICs). In short, yeast cells 118 
5 
 
were standardized to 1 x 104 CFU/mL in Roswell Park Memorial Institute 1640 (RPMI) media. 119 
These were then inoculated in 96-well round bottom plates (Corning, UK) containing serial 120 
double dilutions of chitosan (ranging from 0.68 to 350 mg/l), and pMICs visually determined 121 
after 24 - 48 h. For comparative purposes, conventional anti-fungal (Fluconazole, 122 
Amphotericin B and Echinocandins; Micafungin and Caspofungin) PMIC testing was also 123 
done for all eight isolates as assessed by broth microdilution method in a similar manner as 124 
described above.  125 
For biofilm (sessile) MICs (sMICs), the XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-126 
tetrazolium-5-carboxanilide salt [Sigma-Aldrich, UK]) metabolic reduction assay was used, as 127 
described elsewhere (26). In brief, biofilms were formed by culturing yeast cells at 1 x 106 128 
CFU/mL in RPMI media in flat-bottom wells of 96-well plates (Corning, UK) for 24 h at 37oC, 129 
prior to treatment for an additional 24 h. The sMIC50 and sMIC80 corresponds to the 130 
concentration that resulted in 50% and 80% reduction of XTT readings when compared to 131 
the untreated positive control. All MIC tests were carried out on two separate occasions in 132 
quadruplicate wells of a 96-well plate. For all experiments, appropriate negative controls 133 
minus inoculum were included on each plate in quadruplicate.    134 
Galleria mellonella infection model 135 
Two isolates of C. auris (one non-Agg isolate, NCPF 8973 and one Agg isolate, NCPF 8978) 136 
were selected for Galleria mellonella killing assay as previously described (14). G. mellonella 137 
larvae were infected with these two isolates in the presence and absence of chitosan in a 138 
similar manner to as described elsewhere (27-29). In short, ten sixth-instar G. mellonella 139 
larvae (Livefoods Direct, Ltd., UK) weighing between 200 and 300 mg were selected for each 140 
test group. For infection, a 50 µl Hamilton syringe equipped with 26-gauge needle was used 141 
to inject C. auris into the Galleria; 10 µl of C. auris (2.5 x 105 cells/Larva) were inoculated 142 
through the hindmost right proleg of each larva. The infected larvae were placed in sterile 143 
Petri dishes and incubated at 37°C for 2 h. After this period, larvae were injected in the last 144 
left proleg with chitosan at different concentrations (50, 100 and 200 mg/kg). Larvae 145 
inoculated with PBS and the highest dose of chitosan alone (e.g., 200 mg/kg) were also 146 
included as controls. The percentage survival of the larvae was monitored every 24 h over 4 147 
days. A larva was considered dead when it displayed no movement in response to touch 148 
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together with a dark discoloration of the cuticle. The experiment was repeated on three 149 
separate occasions with 10 larvae per group.  150 
RNA extraction and differential gene expression analysis in C. auris 151 
RNA was extracted from infected and uninfected larvae as follows. Three larvae from each 152 
experimental group were snap-frozen in liquid nitrogen and ground to a fine powder by 153 
mortar and pestle in TRIzol™ prior to bead beating with 0.5 mm glass beads using a BeadBug 154 
microtube homogeniser for a total of 90 seconds (Benchmark-Scientific, New Jersey, USA). 155 
RNA was then extracted using the RNeasy Mini Kit according to manufacturers’ instructions 156 
(Qiagen Ltd, Crawley, UK) and quantified using a NanoDrop 1000 spectrophotometer 157 
[Thermo Scientific, UK]. RNA was converted to complementary DNA (cDNA) using the High 158 
Capacity RNA to cDNA kit (Life Technologies, Paisley, UK) as per the manufacturer’s 159 
instructions. Gene expression of the C. auris infected in the larvae was determined using 160 
quantitative polymerase chain reaction (qPCR) from a total of three individual larvae, each 161 
taken from three independent experiments. For qPCR analyses, the StepOne Plus PCR 162 
machine was used with the following PCR thermal profiles; holding stage at 50˚C for 2 163 
minutes, followed by denaturation stage at 95˚C for 10 minutes and then 40 cycles of 95˚C 164 
for 3 seconds and 60˚C for 15 seconds. Expression levels of each gene of interest were 165 
calculated using the ΔΔCT method (30), with expression normalized to house-keeping gene 166 
β-actin. qPCR gene expression data was presented as % expression relative to house-167 
keeping gene or Log2 fold change in untreated and treated NCPF 8973 relative to NCPF 168 
8978. All primer sequences used for qPCR are shown in Table 2.    169 
DNA extraction for calculating fungal burden in Galleria model 170 
Uninfected and infected Galleria larvae were processed as above for RNA extraction before 171 
a back-extraction buffer (50 mM sodium citrate, 4 M guanidine thiocyanate and 1M Tris [pH 172 
8.0]) was used to extract DNA from samples as previously described (27). Colony-forming 173 
equivalents (CFE) of C. auris were then determined using ITS gene primers (sequences 174 
shown in Table 2) by qPCR and CFE/mL quantified using a standard curve methodology of 175 
fungal colony forming units (CFU). Briefly, CFUs of C. auris NCPF 8973 and NCPF 8978 that 176 
equate to 1 × 103 to 1 x 108 cells/mL were determined using a haemocytometer prior to 177 
DNA extraction. DNA extracted from 1 × 103 to 1 x 108 cells/mL of C. auris was used for 178 
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quantitative analyses using qPCR to generate a standard curve. All samples, including 179 
standards were run in duplicate for qPCR analyses. Fungal load was calculated from a total 180 
of three individual infected larvae each taken from three independent experiments. 181 
Scanning and transmission electron microscopy 182 
For scanning electron microscopy (SEM), non-Agg C. auris (NCPF 8973) and Agg C. auris 183 
(NCPF 8978) were grown as described above. Biofilms were then prepared as above by 184 
growth in RPMI-1640 medium on 13 mm Thermanox™ coverslips (Fisher Scientific, UK) 185 
placed in the bottom of 24-well microtiter plates (Corning, UK) for 24 h at 37°C. After 186 
incubation, biofilms were treated with chitosan at 40 or 80 mg/l (diluted in RPMI-1640 187 
medium) for an additional 24 h then prepared for scanning electron microscopy (SEM) as 188 
previously described (31). In brief, following incubation chitosan-treated and untreated 189 
biofilms were washed three times with PBS prior to fixation in a solution containing 2% 190 
glutaraldehyde, 2% paraformaldehyde, 0.15% alcian blue and 0.15 M sodium cacodylate (pH 191 
7.4). Biofilms were then sputter-coated with gold and viewed under a JEOL JSM-6400 192 
scanning electron microscope (JEOL Ltd, Hertfordshire, UK). All SEM images included in this 193 
study were captured at 15,000 x magnification.  194 
For transmission electron microscopy (TEM), samples were prepared as follows. Non-agg C. 195 
auris (NCPF 8973) and Agg C. auris (NCPF 8978) were grown in YPD as described above then 196 
standardised to 1x108 cells/mL in PBS. A total of 1 mL aliquots of each isolate were 197 
transferred to Eppendorfs and treated for an additional 24 hours, planktonically, with 198 
chitosan at 40 mg/l diluted in RPMI-1640 medium. Post-treatment, the samples were 199 
centrifuged at 13,000 x rpm for 5 minutes, supernatants discarded, and pellet retained for 200 
TEM and prepared for imaging as previously described (32). Following preparation, samples 201 
were embedded in araldite/Epon 812 resin and sectioned using a LEICA ultracut UCT and 202 
DIATOME diamond knife. Samples were imaged on a JEOL1200EX TEM running at 80 kV. All 203 
TEM images included in this study were captured at 6000 x or 25,000 x magnification. 204 
Statistical analysis 205 
Statistical analyses were performed using GraphPad Prism (version 8; GraphPad Software 206 
Inc., La Jolla, CA). Two-tailed Student’s t-tests were used to compare the means of two 207 
samples or one-way analysis of variance (ANOVA) to compare the means of more than two 208 
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samples. Tukey’s post-test was applied to the p value to account for multiple comparisons of 209 
the data. Where appropriate, statistical tests on qPCR gene expression data were completed 210 
on ΔCT values. Pooled data from three independent experiments of G. mellonella larvae 211 
killing assay were assessed using the Kaplan–Meier method, and treatment groups were 212 
compared by the log-rank (Mantel–Cox) test. P-values of < 0.05 were considered statistically 213 
significant for all tests. 214 
Results 215 
Given the well-established drug resistance profile of C. auris (4), we sought to assess the 216 
antimicrobial potential of chitosan, a polymer purported to have broad spectrum activity. 217 
We assessed the activity of chitosan against a selection of C. auris isolates with different 218 
phenotypes, both in vitro and in vivo. Firstly, the minimum inhibitory concentration for 219 
planktonic (PMIC) and sessile (SMIC) cells were determined for a total of eight different 220 
isolates of C. auris (four non-Agg and four Agg isolates, as shown in Table 1). All isolates 221 
used possessed similar sensitivity profiles to conventional antifungals as based on sensitivity 222 
profiles reported previously (Table 1) (12, 14). PMIC values varied between 5-20 mg/l 223 
chitosan from all isolates, with the highest PMIC (20 mg/l) observed for two Agg isolates 224 
(NCPF 8977 and NCPF 8978). It is noteworthy that planktonic forms of these two isolates 225 
have previously been shown to be highly resistant to caspofungin (14). The SMIC50 and 226 
SMIC80 values also varied between non-Agg and Agg phenotypes of C. auris. For SMIC50 227 
these values ranged between 10-80 mg/l, and for SMIC80 from 40-160 mg/l. The highest 228 
SMIC80 was detected in the same two Agg isolates as above (160 mg/l; NCPF 8977 and NCPF 229 
8978, respectively). Interestingly, there was a certain level of heterogeneity observed in the 230 
non-Agg and Agg isolates response to chitosan treatment irrespective of aggregative 231 
phenotype.  232 
Next, 24-hour chitosan-treated C. auris biofilms were visualised using scanning and 233 
transmission electron microscopy (SEM and TEM) to assess the ultra-structure and 234 
morphology of the cells after treatment. For these and subsequent studies, one non-Agg 235 
(NCPF 8973) and one Agg (NCPF 8978) isolate was selected for analysis. In SEM, at 15,000 x 236 
magnification, morphological differences in the sessile C. auris cells were observed after 237 
exposure to chitosan. Untreated non-Agg C. auris biofilms displayed singular oval-shaped 238 
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yeast cells (Figure 1A), while Agg phenotype of C. auris resulted in clusters or “aggregates” 239 
of oval-shaped yeast cells (Figure 1B). At both concentrations of chitosan (40 and 80 mg/l), 240 
the drug can be seen coating and encapsulating C. auris cells in the biofilms (Figure 1C-F). 241 
Intriguingly, the higher concentration of chitosan appeared to adsorb to the cell surface and 242 
puncture the non-Agg C. auris cell, resulting in a deflated appearance likely resulting from 243 
cell death (white arrow; Figure 1E). At the same concentration, chitosan can be seen coating 244 
the Agg C. auris, however, with no obvious change in morphology (Figure 1F). Such a 245 
discrepancy in ultra-structure between the two phenotypes may correlate with the 246 
differences in MICs as shown in Table 1, whereby 80 mg/l was two times the SMIC80 for the 247 
non-Agg C. auris NCPF 8973.    248 
Further analyses into the interactions between chitosan and C. auris were achieved using 249 
transmission electron microscopy (TEM). TEM images showed that chitosan particles coated 250 
the cells of both C. auris isolates (Figure 2). Untreated cells for non-Agg and Agg C. auris 251 
appear darkened, with dense intracellular material and a thick, uniform cell wall (Figure 2A 252 
and 2B). Following treatment with 40 mg/l of chitosan, particles of the compound are seen 253 
coating the cell walls/membranes of both isolates (denoted by red arrows; Figure 2C and 254 
2D). At higher magnification, accumulation of chitosan is evident in periphery of the cell, 255 
leading to penetration of the cell wall and membrane (white arrows; Figure 2C and 2D, right 256 
panels). Interestingly, chitosan-coated cells for both isolates appear transparent with 257 
evidence of a loss of cell morphology and/or cell components, potentially resulting from an 258 
efflux of intracellular material following penetration of the cell by the compound.  259 
Given the differences in Agg and non-Agg C. auris response to chitosan in vitro, the efficacy 260 
of chitosan was next tested in vivo in a G. mellonella infection model. Firstly, the virulence of 261 
non-Agg and Agg C. auris was assessed in the model using a Kaplan-Meier plot to monitor 262 
the survival of infected G. mellonella larvae over 4 days post-infection. Similar to previous 263 
studies, the non-Agg NCPF 8973 was significantly more virulent than the Agg NCPF 8978 264 
isolate. Infection with NCPF 8973 resulted in killing of approximately ~47% of the larvae four 265 
days post-infection, while following infection with NCPF 8978 almost 80% of the larvae 266 
remained alive (Figure 3). Following treatment with chitosan, the compound ameliorated 267 
the killing effects of both C. auris isolates in the infection model. After treatment, at the 268 
highest concentration, 200 mg/kg chitosan significantly increased the survival rates of the 269 
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larvae infected with NCPF 8973 from approximately 55% to 84% (Figure 3A; **** p<0.0001 270 
according to log-rank test). For the Agg phenotype, in comparison to the untreated group, 271 
survival rates of Agg C. auris-infected larvae were significantly increased to ~87% from ~75% 272 
when treated with 200 mg/kg chitosan (Figure 3B; * p<0.05).  273 
In order to provide mechanistic insights behind the observed protective effect of chitosan in 274 
vivo, fungal load and C. auris gene expression was determined in the infected larvae +/- 275 
chitosan treatment. Firstly, fungal load in larvae was significantly reduced following 276 
treatment with chitosan (200 mg/kg) for both non-Agg and Agg infection models (Figure 4A 277 
and B, both * p<0.05 respectively). For gene expression analyses in the fungi, expression of 278 
genes related to adhesion (ALS5, HYR3), hydrolytic enzymes (SAP5, PLB1), cell wall, cell 279 
membrane and extracellular matrix (ERG2, KRE6, EXG, ENG1) were investigated in relation 280 
to the housekeeping gene β-actin. These candidate genes were selected for analyses as 281 
previously described; these and similar genes are differentially regulated in early and 282 
mature biofilms of C. auris (33). Expression of all genes arrayed (with the exception of SAP5) 283 
were upregulated in the non-Agg C. auris isolate when presented as Log2 fold change 284 
relative to the Agg isolate (Figure 5). All genes were upregulated in the non-Agg isolate 285 
following treatment with the highest concentration of chitosan, compared to the untreated 286 
controls (Supplementary Figure 1; white bars). The greatest change in expression were seen 287 
for ALS5, changing from ~0.49% average expression in untreated controls, to ~13.02% 288 
average expression following treatment with 200 mg/kg chitosan (Supplementary Figure 289 
1B). For the Agg isolate, SAP5 was the only gene upregulated following treatment with the 290 
highest chitosan concentration (Supplementary Figure 1C; ~1.18% in the untreated controls 291 
compared to ~21.88% for 200 mg/kg). EXG and ENG1 were the most downregulated genes; 292 
expression changed from 8.92% and 6.41% in controls compared to 0.98% and 0.27% for 293 
200 mg/kg chitosan-treated. Taken together, following treatment, chitosan appeared to 294 
induce a stress-like response in the non-Agg isolate compared to Agg isolate (Figure 5).  295 
Discussion  296 
Given the propensity for C. auris to be resistant to a wide range of azoles, polyenes, and 297 
echinocandins (4, 34), alternative treatment methods need to be explored. Here, a naturally 298 
derived compound called chitosan was shown effective against Agg and non-Agg isolates of 299 
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C. auris both in vitro and in vivo. Recently, the compound was shown to be effective against 300 
C. albicans and other Candida species (16-19); the proposed mechanism of action being that 301 
positively charged chitosan molecules interact with negatively charged cell membranes 302 
leading to release of proteinaceous and intracellular constituents, causing cell death (15, 35, 303 
36). Here we were able to show that Agg and non-Agg C. auris planktonic and sessile cells 304 
were susceptible to chitosan treatment in vitro. Using microscopic analyses, the chitosan 305 
can be visualised coating the cell surface of the C. auris resulting in an altered morphological 306 
phenotype likely arising from cell death. In addition, C. auris fungal load was reduced and its 307 
virulence ameliorated in vivo in a Galleria infection model following treatment with the 308 
compound. Interestingly, chitosan treatment induced a stress-like gene response in the 309 
more susceptible non-Agg isolate infected in the larvae.  310 
C. auris isolates possess unique strain-specific variability in biofilm formation and virulence 311 
(10, 12, 14). Two types of C. auris isolates exist; one that forms an aggregative phenotype in 312 
vitro, and the second that forms single cell biofilms (12, 14). Therefore, studies must 313 
account for these differences in aggregative phenotype when studying the effects of 314 
potential therapeutics against C. auris. As such, this study initially tested the susceptibility of 315 
four Agg and non-Agg isolates of C. auris to chitosan. Interestingly, C. auris response to 316 
chitosan exhibited a level of heterogeneity in the Agg and non-Agg isolates. These 317 
observations are in line with a previous study showing variation in planktonic and sessile 318 
MICs for a number of C. auris isolates taken from intensive care unit or candidemic patients 319 
against a wide range of conventional antifungal therapies such as Amphotericin B, 320 
Fluconazole and Caspofungin (37). Given the high level of heterogeneity amongst isolates to 321 
different antifungals, future work merits consideration for direct comparative studies 322 
testing novel therapeutics and conventional antifungals against isolates with different 323 
phenotypes from various clades.   324 
MIC testing results indicated that two isolates, NCPF 8973 and NCPF 8978, had the lowest 325 
and highest PMIC and SMIC80, of the initial pool, respectively. Therefore, we hypothesized 326 
these two isolates would provide accurate representations for the effects of chitosan 327 
against the Agg and non-Agg phenotypes. For these two isolates, the PMIC and SMIC values 328 
were higher for the Agg phenotype. This finding may be explained by Agg phenotype of C. 329 
auris providing a protective barrier to therapeutics. Indeed, we have recently shown that 330 
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Agg C. auris NCPF 8978 possesses the ability to survive and persist on surfaces in response 331 
to sodium hypochlorite treatment, even after 14 days post-treatment. Conversely, the non-332 
Agg isolate C. auris NCPF 8973 was susceptible to such treatment (10). Here, it was evident 333 
from the SEM imaging that the non-Agg C. auris is visibly encapsulated by the chitosan 334 
compound leading to an altered morphology at the higher concentration of drug, whilst in 335 
the aggregative phenotype, there appears no change in cellular ultrastructure, suggestive of 336 
a protective phenotype when cells are present in aggregates. The altered morphology in the 337 
non-Agg isolate SEMs likely arose from chitosan-mediated cell death. In agreement, a 338 
publication by Ganan et al (2019) recently used confocal microscopic imagery to show that 339 
an oligosaccharide of chitosan (chito-oligosaccharide) generated from chemical or 340 
enzymatic digestion of chitosan was capable of adsorbing to yeast cells of C. albicans, 341 
subsequently disrupting cellular structure and accumulating in the cytoplasm (17). Indeed, 342 
TEM images confirmed that chitosan, albeit at a concentration above the PMIC for both 343 
isolates (e.g., 40 mg/l), was visualised coating the organism, penetrating the cell walls 344 
resulting in a loss of cellular morphology and efflux of intracellular material. Moving 345 
forward, it would be of interest to quantify the level of adsorption and cell wall/membrane 346 
damage in the C. auris isolates following treatment with the antifungal. However, such 347 
techniques as SEM and TEM are qualitative in nature, with no accurate way of quantifying 348 
the level of cellular damage.  349 
In the Galleria model to assess C. auris virulence, the non-Agg C. auris NCPF 8973 induced 350 
significantly greater killing of the larvae than the Agg isolate, NCPF 8978. This is in 351 
agreement with previous studies from our group and others (12, 14), although why such 352 
phenomena arise is unknown. It could be postulated that single cellular forms of C. auris can 353 
disseminate more rapidly in vivo than Agg isolates, leading to increased killing rates. Others 354 
have shown that phenotypic form of C. auris can switch from yeast to filamentous 355 
morphology following ‘passage’ through a mammalian body, suggestive that phenotypic 356 
state is inducible under certain conditions (38). It would be of interest to assess whether 357 
such phenomena occur in G. mellonella larvae infected with non-Agg C. auris, which could 358 
explain its enhanced virulence traits in this model. Nevertheless, we were able to show that 359 
chitosan treatment ameliorated the C. auris virulence in this infection model, likely arising 360 
from reduced fungal load in the larvae. In a similar manner to results presented here, 361 
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several research groups have recently reported the use of novel antifungal compounds 362 
against C. auris in vitro and in vivo (39-41). However, such in vivo studies are generally 363 
limited to studying individual isolates or isolates with similar Agg or non-Agg phenotypes. 364 
Such Agg or non-Agg characteristics need to be considered particularly given that similar 365 
murine infection models have shown that C. auris aggregates can accumulate in tissues of 366 
infected animals (13). Therefore, we deemed it pertinent to study the effects of possible 367 
antifungal therapeutics against different C. auris aggregates in vivo. However, it must be 368 
stated that the in vivo observations described here are limited to one non-Agg and one Agg 369 
isolate. Therefore, assumptions about the effects of the chitosan on other isolates in similar 370 
model systems cannot be made without further studies, particularly given the high level of 371 
heterogeneity amongst isolates to the antifungal.  372 
Finally, differential gene expression of the Agg and non-Agg C. auris was observed in the 373 
Galleria model with chitosan treatment. Several candidate genes involved in important 374 
virulence pathways associated with biofilm formation and resistance were selected for 375 
comparative expression analyses in the isolates. Although such analyses were limited to one 376 
isolate for each phenotype, results were indicative of a unique stress-like response in the 377 
non-Agg phenotype following treatment with chitosan in vivo, evident by an up-regulation 378 
in expression of most of the genes arrayed. In a similar manner, others have identified that 379 
chitosan can interfere in gene expression in other Candida species. In addition to chitosan 380 
penetrating the cell wall and membrane of the cell leading to cell death (15, 35, 36), it is 381 
postulated that the compound is able to breach the nucleus of the fungal cell interfering 382 
with the synthesis of mRNA and translation of proteins (42). An in vitro study recently 383 
showed that chitosan represses the function of the SAGA (Spt-Ada-Gcn5 acetyltransferase) 384 
complex in C. albicans by downregulating ADA2 and associated genes, which are involved in 385 
encoding for proteins involved in maintaining cell wall and membrane integrity (16). 386 
Conversely, it could be postulated that the stress-like response of NCPF 8973 to chitosan 387 
may simply have resulted from an increased susceptibility to the compound (as shown by 388 
the in vitro MIC tests). Conclusive elucidation of the mechanistic response seen in C. auris to 389 
chitosan is currently unknown and requires further investigation.  390 
Direct physical interactions between chitosan and the cell wall may provide an alternative 391 
mechanism by which the drug affects gene expression in C. auris. It is not uncommon for 392 
14 
 
antifungal therapies to induce such stress-like responses in Candida species, particularly in 393 
vitro (43, 44). For example, echinocandins such as Caspofungin which target β-glucan 394 
synthesis pathways can exert stress upon the cell wall leading to attenuated efficacy against 395 
C. albicans at high concentrations (45). Similar drug resistance profiles have recently been 396 
described for C. auris to echinocandins, resulting from a mutation FKS1 gene, which encodes 397 
for a 1-3-β-glucan synthase enzyme (46). Interestingly, in our analyses we found an 398 
upregulation in genes associated with cell wall component assembly/disassembly and cell 399 
separation pathways in the non-Agg C. auris in increasing concentrations of chitosan. In 400 
particular, the genes KRE6 (involved in β-1,6-glucan synthesis), EXG and ENG1 (exo‐β‐1,3‐401 
glucanase and endo‐β‐1,3‐glucanase, involved in cell separation) were upregulated in the 402 
non-Agg phenotype following treatment of the Galleria larvae with the drug. Such genes 403 
have been shown important in virulence of other fungal species. Disrupting the β-1,6-glucan 404 
synthesis pathway by targeting KRE6 and a related gene SKN1 reduced growth and biofilm-405 
forming rates of C. albicans, interfered with cell separation and cell wall formation, and 406 
attenuated its virulence in a murine model (47). Furthermore, mutation of ENG1 impaired 407 
virulence of Histoplasma yeasts in vivo (48). Therefore, it could be postulated that the gene 408 
expression profiles observed in study may be indicative of a response by the organism to 409 
upregulate cell wall β-glucan synthesis and cell separation in an attempt to promote survival 410 
and circumvent the antifungal effect of chitosan.  411 
Similar gene expression responses were not seen in the Agg isolate of C. auris following 412 
treatment with chitosan. Such a result is difficult to interpret without further studies on this 413 
and other Agg isolates. However, in vitro observations from this study showed that the Agg 414 
isolate was more resistant to chitosan treatment than the non-Agg counterpart, which could 415 
explain the observed gene expression profile in vivo. As discussed above, the aggregative 416 
phenotype may simply provide a physical barrier for chitosan delivery to the cell. Indeed, 417 
this aggregative phenomenon may exist both in vitro and in vivo. Ben-Ami and colleagues 418 
recently recovered large aggregates of C. auris cells from harvested tissue of a murine 419 
model following infection, which could be a strategy used to evade the host response (13). 420 
Nevertheless, the clinical implications of aggregation in C. auris remain limited, although 421 
such phenomena have been considered for other microorganisms. The formation of 422 
aggregates in bacteria such as Pseudomonas aeruginosa enhances tolerance traits such as 423 
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antibiotic resistance and/or evasion of the host response (49, 50). It would be of great 424 
interest to assess whether such C. auris isolates can form aggregates in Galleria tissues, and 425 
whether non-Agg isolates persist as single cells in vivo. If achievable, this could begin to 426 
elucidate the resistance mechanisms utilised by C. auris against antifungals.  427 
In conclusion, this is the first study to show that the naturally derived molecule chitosan 428 
may be effective against the putative opportunistic environmental yeast, C. auris. We and 429 
others have shown here and in previous studies that the aggregative phenotypes of 430 
different C. auris isolates dictate the response of the organism to antifungals (8, 9, 12, 14). 431 
As such, future studies must continue to investigate these unique aggregative phenotypic 432 
traits of C. auris isolates from different clades to fully comprehend the response of such 433 
isolates to conventional and novel therapeutics.     434 
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Phenotype Strain Clade  PMIC [mg/l] SMIC50 [mg/l] SMIC80 [mg/l] 




5 40 40 




10 40 80 




10 40 80 
Non-Agg C. auris 199 (FluR, 
AmpI, EchS) 
Unknown 10 10 80 
Agg C. auris 8977 (FluR, 
AmpI, EchS) 
South African 20 40 160 
Agg C. auris 8978* (FluR, 
AmpI, EchS) 
South African 20 80 160 
Agg C. auris 8983 (FluR, 
AmpI, EchS)   
Southern 
Asian/Indian 
5 40 40 
Agg C. auris 8986 (FluR, 
AmpI, EchS)  
Southern 
Asian/Indian 
10 20 40 
 611 
Table 1 – Planktonic and sessile minimum inhibitory concentrations of chitosan against 612 
eight isolates of Candida auris. Planktonic (pMIC) and sessile minimum inhibitory 613 
concentrations (sMIC) for chitosan against four non-aggregative (non-Agg) and four 614 
aggregative (Agg) isolates of C. auris. For pMICs, the broth microdilution method was 615 
employed. For sMICs, the XTT metabolic reduction assay for used, and the sMIC50 and 616 
sMIC80 corresponds to the concentration that resulted in 50% and 80% reduction of XTT 617 
readings when compared to the untreated positive control. All MIC tests were performed on 618 
2 independent occasions, showing identical results each time. For comparative purposes, 619 
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conventional anti-fungal susceptibility profiles are shown for all eight isolates as assessed by 620 
broth microdilution method and as previously described (12, 14). Abbreviations; FluR; 621 
fluconazole resistant, AmpI; Amphotericin B intermediate, EchI or EchS; Echinocandins 622 
intermediate or susceptible. * denotes the two isolates selected for microscopic analyses 623 





 Gene Direction Sequence (5'–3') 




Table 2 – List of primer sequences used in this study. Forward and reverse primer 628 
sequences for C. auris fungal load quantification and gene expression analyses in this study.  629 
 630 




Forward  GGCTCATCTTGGCTTCCTT 




























Figure 1 – Scanning electron microscopic images of chitosan-treated Candida auris. 632 
Chitosan-treated 24 h biofilms of non-aggregative (non-Agg) NCPF 8973 and aggregative 633 
(Agg) NCPF 8978 C. auris were visualised using scanning electron microscopy (SEM). 634 
Untreated non-Agg and Agg biofilms were used as controls and treated in the same way 635 
minus chitosan (A and B). Non-Agg and Agg biofilms of C. auris were treated with 40 mg/l (C 636 
and D) or 80 mg/l (E and F) for 24 h prior to imaging at 15,000 x magnification. White arrows 637 
highlight the encapsulation of C. auris cells by chitosan particles and deflation in cell 638 
morphology of the non-Agg NCPF 8973 isolate (E).  639 
Figure 2 – Transmission electron microscopic images of chitosan-treated Candida auris. 640 
Planktonic cells of non-aggregative (non-Agg) NCPF 8973 and aggregative (Agg) NCPF 8978 641 
C. auris at 1 x 108 cells/mL were treated with chitosan prior to imaging using transmission 642 
electron microscopy (TEM). Untreated non-Agg and Agg controls were used as comparison 643 
minus chitosan treatment (A and B).  Non-Agg and Agg C. auris were treated with 40 mg/l of 644 
chitosan for 24 h prior to TEM imaging at 6000 x and 25,000 x magnification (C and D).  Red 645 
arrows in lower magnification panels identify the coating of C. auris cell walls with chitosan 646 
particles. White arrows in higher magnification panels highlight penetration of C. auris cell 647 
wall/membranes by chitosan.  648 
Figure 3 – Survival curves of Galleria mellonella following infection with Candida auris. G. 649 
mellonella larvae were infected with 2.5 x 105 cells/larvae of C. auris +/- chitosan treatment 650 
and survival rates monitored every 24 hours for 4 days. A total of 3 chitosan treatments 651 
were used (50 mg/kg; green line, 100 mg/kg; yellow line and 200 mg/kg; blue line). Control 652 
groups received PBS only (black line) or infected with C. auris minus chitosan treatment (red 653 
line). The highest concentration of chitosan had no effect on the survival of the larvae minus 654 
C. auris infection (data not shown). Data representative of results from three independent 655 
experiments with 10 larvae per group are shown in a Kaplan-Meier plot and statistical 656 
differences calculated between treatment groups by the log-rank (Mantel–Cox) test. * 657 
denote significant differences between highest concentration of chitosan (200 mg/kg) and 658 
infected controls minus chitosan treatment (* p < 0.05, **** p < 0.0001). 659 
Figure 4 – Fungal load from Candida auris-infected Galleria mellonella. G. mellonella larvae 660 
were infected with 2.5 x 105 cells/larvae of C. auris +/- chitosan treatment. After 24 h, larvae 661 
were harvested and weighed prior to DNA extraction. The abundance of C. auris (presented 662 
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as colony forming equivalents/g) in the larvae were calculated by quantitative PCR using a 663 
standard curve methodology of fungal colony forming units ranging from 1 × 103 to 108 664 
CFU/mL. Significant differences were calculated using a one-way analysis of variance 665 
(ANOVA) with Tukey’s post-test. Significant differences denoted by * (p < 0.05).  Data 666 
representative of results from three independent experiments.  667 
Figure 5 – Gene expression profile of Candida auris in the Galleria mellonella infection 668 
model. G. mellonella larvae were infected with 2.5 x 105 cells/larvae of C. auris +/- three 669 
concentrations of chitosan treatment (50 mg/kg, 100 mg/kg and 200 mg/kg). After 24 h, 670 
larvae were harvested for RNA extraction. Gene expression was measured by quantitative 671 
PCR, and expression of all genes of interest calculated relative to a house-keeping gene (β-672 
actin). Data presented as mean values from three independent experiments in a heatmap, 673 
calculated as Log2 fold-change of expression in C. auris NCPF 8973 relative to C. auris NCPF 674 
8978 +/- chitosan treatment.  675 
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